McKenna Mark C. 4
4 · Apogee Therapeutics, Inc. · Filed Dec 16, 2024
Insider Transaction Report
Form 4
McKenna Mark C.
Director
Transactions
- Purchase
Common Stock
2024-12-12$49.85/sh+12,500$623,125→ 20,000 total - Purchase
Common Stock
2024-12-12$49.02/sh+7,500$367,650→ 7,500 total
Footnotes (2)
- [F1]The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $48.50 to $49.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $49.6275 to $50.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range.